The response to imatinib and interferon-α is more rapid than the response to imatinib alone: A retrospective analysis of 495 philadelphia-positive chronic myeloid leukemia patients in early chronic phase

Haematologica

Volumn 95, Issue 8, 2010, Pages 1415-1419

  Palandri, Francesca ^a   Castagnetti, Fausto ^a   Iacobucci, Ilaria ^a   Martinelli, Giovanni ^a   Amabile, Marilina ^a   Gugliotta, Gabriele ^a   Poerio, Angela ^a   Testoni, Nicoletta ^a   Breccia, Massimo ^b   Bocchia, Monica ^c   Crugnola, Monica ^d   Rege Cambrin, Giovanna ^e   Martino, Bruno ^f   Pierri, Ivana ^g   Radaelli, Franca ^h   Specchia, Giorgina ⁱ   Pane, Fabrizio ^j   Saglio, Giuseppe ^e   Rosti, Gianantonio ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

ⁱ UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^j CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

more..

Author keywords

Chronic myeloid leukemia; Imatinib; Interferon ; Molecular response

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PEGINTERFERON ALPHA2B;

ADULT; AGED; ARTICLE; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROGRESSION FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956035133     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.021246     Document Type: Article

References (27)

1. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98(10):3074-81
2. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-6.
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
4. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108(6):1809-20.
5. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, Trumpp A, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904-8.
6. Hochhaus A, Yan XH, Willer A, Hehlmann R, Gordon MY, Goldman JM, Melo JV. Expression of interferon regulatory factor (IRF) genes and response to interferonalpha in chronic myeloid leukaemia. Leukemia. 1997;11(7):933-9.
7. Dowding C, Guo AP, Osterholz J, Siczkowski M, Goldman J, Gordon M. Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood. 1991;78(2):499-505.
8. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood. 1996;87(9):3883-91.
9. Gabriele L, Borghi P, Rozera C, Sestili P, Andreotti M, Guarini A, et al. IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood. 2004;103(3):980-7.
10. Oka T, Sastry KJ, Nehete P, Schapiro SJ, Guo JQ, Talpaz M, Arlinghaus RB. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia. 1998;12(2):155-63.
11. Burchert A, Wölfl S, Schmidt M, Brendel C, Denecke B, Cai D, et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003; 101(1):259-64.
12. Deng M, Daley GQ. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood. 2001; 97(11):3491-7.
13. Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood. 2001; 97(11):3648-50.
14. Hehlmann R, Saussele S, Lauseker M, Leitner A, Pletsch N, Haferlach C, et al. Randomized clinical trial for the optimization of imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV. Haematologica. 2009; 94 (suppl.2):193 abs. 0478
15. Guilhot F, Preudhomme C, Guilhot J, et al. Significant Higher Rates of Undetectable Molecular Residual Disease and Molecular Responses with Pegylated Form of Interferon a2a in Combination with Imatinib (IM) for the Treatment of Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukaemia (CML) Patients (pts): Confirmatory Results at 18 Months of Part 1 of the Spirit Phase III Randomized Trial of the French CML Group (FI LMC). Blood (ASH Annual Meeting Abstracts) 114: abstract 340,2009.
16. Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. Imatinib and pegylated human recombinant interferon-alpha2b in early chronicphase chronic myeloid leukemia. Blood. 2004;104(13):4245-51.
17. Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, et al. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alfa: 5-year outcome. Haematologica. 2008;93(5):770-4.
18. Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of highrisk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood. 2009; 113(19): 4497-504.
19. Rosti G, Palandri F, Castagnetti F, Iacobucci I, Marzocchi G, Testoni N, et al; on behalf of the GINEMA Working Party on CML. Front-line treatment of Philadelphia-positive chronic myeloid leukemia patients at low Sokal risk with Imatinib 400 mg. A multicentric study of the GIMEMA CML WORKING PARTY. Haematologica. 2007; 92 (suppl 3):3.
20. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'realtime' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-57.
21. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
22. Mahon F-X, Rea D, Guilhot F, et al. Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients. Blood (ASH Annual Meeting Abstracts) 114:abstract 859,2009.
23. Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(3): 424-30.
24. Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, et al; Australasian Leukaemia and Lymphoma Group. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112(10):3965-73.
25. Cortes JE, Jones D, O'Brien S, Jabbour E, Konopleva M, Ferrajoli A, et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol. 2010;28(3):392-7
26. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood. 2009;114(24): 4933-8.
27. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010;28(3):398-404.